From Barron's 5-14-07 "[Jewelry retailer] Blue Nile reported 1Q07 earnings of 19 cents per share, handily beating consensus of 15 cents per share and prior-year earnings of 13 cents, and the top end of management's guidance range....Revenues increased 34% year-over-year to $67.9 million....Particularly strong were sales of high-end diamonds. Based, in part, on management's updated guidance, we've revised our 2007 estimate ...[to] 92 cents per share, versus prior 86-cent estimate....Despite strength, stock appears fully valued...it trades at 51.5 times our revised '07 earnings estimate. Raising target to 45 from 34, or 49 times our '07E; reiterate Hold."

From Barron's 5-14-07 "Maintain Buy and 7 target. We continue to believe Così [owner, operator and franchiser of ~130 café units; firm's market-cap, $192 million] has potential to grow units and revenue in excess of 20%, compared to our estimate of 8% industry revenue growth. Our target continues to be based on a 20% discount to the 1.7 times enterprise value/'07 estimated revenue multiple of Così's quick-casual peers, reflecting Così's relative size and liquidity."

From Barron's 5-14-07 "Cutera laser and light-based systems...[are used by] dermatologists, surgeons...and others practitioners. Cutera preannounced 13% revenue shortfall, but doubt remained about whether problems were affecting Cutera specifically or whole cosmetic-laser industry, [or if they were] nonrecurring....We [don't] expect shortfall to carry through rest of '07....Our new 29 target (prior: 39) is, net of $7 cash, 17.6 times our one-year forward (2Q08-1Q09) earnings-per-share forecast of $1.25, at 1.1 PEG [price-to-earnings-growth], below med-tech mean."

From Barron's 5-14-07 "Radio broadcaster ETM [100+ stations in 23 U.S. markets] reported EPS of a 1-cent loss, close to our estimate of 0 cents...it included a one-time tax charge, which our estimate reflected. The EPS would have been 9 cents on adjusted basis....M&A activity has been significant, potentially strengthening results in the future but complicating comparisons in current time frame and adding to expense levels...there will be an increase in Red Sox sports rights amortized over the months of baseball season. Favorably, a newly acquired station is being used to simulcast these games and extend other sports programming to a broader market."

From Barron's 5-14-07 "Target: 22. GSOL is one of the largest B2B commerce companies in China....We believe GSOL is well positioned for...positive trends including international-trade growth, adoption of online marketing...and [a] strategy to cross-sell services across multiple media platforms. However, a tough industry environment...and other emerging companies are key risks....Our target implies 19 times our '08 EPS estimate plus cash."

From Barron's 5-14-07 "Pfizer managed to report a decent top-line growth of 6% year-over-year in Q1 [of calendar] '07, unlike in the past, where top-line growth was almost flat and much of the EPS upside was achieved on...cost-controls...EPS [was] 68 cents, 11 cents ahead of our and consensus estimates. However... management deci[ded] to lower full-year EPS guidance range by 10 cents, despite strong quarterly performance, to incorporate earlier-than-expected entry of Norvasc generics and maintain earlier revenue guidance range of $47 billion to $48 billion."